Biotech Archives - Page 660 of 733

2 minute read

Adamis Provides An Enrollment Update On The Phase 2/3 Study Of Tempol In COVID-19 Positive High-Risk Subjects

September 12, 4:09 PM

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the

ADMP

1 minute read

Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate

By Ragothaman Srinivasan

September 12, 3:29 PM

Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies. This global Phase 2 program include clinical trials of ACTIVATE-Colorectal and ACTIVATE-Melanoma studies.

AGEN

1 minute read

BioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate

By Ragothaman Srinivasan

September 12, 3:01 PM

BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.

BLRX

1 minute read

Analyst Outlines Doubts On This NASH-Focused Stock, Builds Neutral Case

By Vandana Singh

September 12, 2:24 PM

HC Wainwright initiated Terns Pharmaceutical Inc (NASDAQ:TERN) with a Neutral rating and a price target of $6.00. The biopharmaceutical company has a…

TERN

1 minute read

This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says

By Vandana Singh

September 12, 2:21 PM

HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ:RAIN), with a price target of $10 with a Buy rating. With an upside…

DSNKY

1 minute read

Deciphera Earns Price Target Bump With Encouraging ESMO Presentation

By Vandana Singh

September 12, 1:38 PM

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…

DCPH

1 minute read

IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial

By Vandana Singh

September 12, 1:22 PM

The shares of oncology-focused Ideaya Biosciences Inc (NASDAQ: IDYA) are trading higher after interim data from its solid tumor candidate darovasertib with cancer…

IDYA